Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01517984 · ClinicalTrials.gov registry record · Phase 2
Immune Monitoring and CNI Withdrawal in Low Risk Recipients of Kidney Transplantation
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Terminated
- Registry status
- Phase 2
- Development phase
- 52
- Enrollment target
NCT01517984 is a Phase 2 study that was terminated before completion, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 52 participants.
The verdict
NCT01517984, a Phase 2 study, was terminated before completion, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 52 participants
- Enrollment target
Study Summary
The study will compare how well transplanted kidneys work and the response of people's immune systems as tacrolimus, a calcineurin inhibitor (CNI), is withdrawn. In addition, this research study will evaluate whether reducing immunosuppression can decrease some of these side effects while still preventing rejection of the kidney.
Interventions
- DRUG Tacrolimus (CNI) Withdrawal
- DRUG Standard Immunosuppressive Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2010-11 |
| Est. Completion | 2015-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01517984
The ClinicalTrials.gov registry entry for NCT01517984 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tacrolimus (CNI) Withdrawal is the first listed.
NCT01517984 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01517984 about?
NCT01517984 is a clinical study titled "Immune Monitoring and CNI Withdrawal in Low Risk Recipients of Kidney Transplantation". The study will compare how well transplanted kidneys work and the response of people's immune systems as tacrolimus, a calcineurin inhibitor (CNI), is withdrawn. In addition, this research study will evaluate whether reducing immunosuppression can decrease some of these side effects while still prev...
What is the current status of trial NCT01517984?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2010-11. Estimated completion is 2015-05.
What interventions are being tested in trial NCT01517984?
The interventions under investigation include: Tacrolimus (CNI) Withdrawal (DRUG), Standard Immunosuppressive Therapy (DRUG).
Who is sponsoring clinical trial NCT01517984?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.